Enzychem Lifesciences Corporation (KOSDAQ:183490)
South Korea · Delayed Price · Currency is KRW 990.00
-27.00 (-2.65%)
Mar 25, 2026, 7:48 AM KST
Enzychem Lifesciences Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 61,860 | 67,751 | 77,378 | 76,039 | 26,638 | 22,975 |
Other Revenue | - | - | -0 | - | -0 | - |
| 61,860 | 67,751 | 77,378 | 76,039 | 26,638 | 22,975 | |
Revenue Growth (YoY) | -18.52% | -12.44% | 1.76% | 185.46% | 15.94% | -11.01% |
Cost of Revenue | 59,729 | 64,368 | 73,068 | 71,691 | 24,221 | 22,689 |
Gross Profit | 2,131 | 3,383 | 4,310 | 4,348 | 2,416 | 286.72 |
Selling, General & Admin | 12,937 | 12,931 | 12,215 | 12,017 | 9,834 | 10,859 |
Research & Development | 3,163 | 3,546 | 4,421 | 5,434 | 6,558 | 9,501 |
Amortization of Goodwill & Intangibles | 387.09 | 405.96 | 411.31 | 533.08 | 271.55 | 231.12 |
Operating Expenses | 20,541 | 21,654 | 20,686 | 19,081 | 17,078 | 21,040 |
Operating Income | -18,409 | -18,270 | -16,376 | -14,733 | -14,662 | -20,754 |
Interest Expense | -189.22 | -201.47 | -238.7 | -620.09 | -10,030 | -9,508 |
Interest & Investment Income | 3,655 | 3,817 | 5,207 | 5,489 | 3,976 | 963.71 |
Earnings From Equity Investments | -987.45 | -770.19 | -2,176 | 26.87 | -13.64 | -445.14 |
Currency Exchange Gain (Loss) | 62.91 | -102.28 | 244.33 | -34.38 | -164.71 | -60.59 |
Other Non Operating Income (Expenses) | 1,445 | 1,203 | -6,660 | 41.19 | -7.09 | 292.36 |
EBT Excluding Unusual Items | -14,423 | -14,324 | -20,000 | -9,830 | -20,901 | -29,512 |
Gain (Loss) on Sale of Investments | -16.51 | -16.98 | -1,938 | 3.65 | 3.57 | 4.39 |
Gain (Loss) on Sale of Assets | -127.35 | -156.11 | -0.45 | -19.5 | 8.12 | -13.27 |
Asset Writedown | -3,728 | -3,743 | -145.56 | -32.74 | -4,692 | 16.05 |
Pretax Income | -18,294 | -18,240 | -22,084 | -9,879 | -25,581 | -29,504 |
Income Tax Expense | -130.53 | -147.22 | 3.12 | -476.3 | -488.27 | -1,640 |
Earnings From Continuing Operations | -18,164 | -18,092 | -22,088 | -9,403 | -25,093 | -27,865 |
Minority Interest in Earnings | 43.26 | -39.15 | -19.01 | 76.24 | - | - |
Net Income | -18,121 | -18,132 | -22,107 | -9,326 | -25,093 | -27,865 |
Preferred Dividends & Other Adjustments | - | - | - | - | -159.59 | -941.77 |
Net Income to Common | -18,121 | -18,132 | -22,107 | -9,326 | -24,934 | -26,923 |
Shares Outstanding (Basic) | 77 | 77 | 82 | 85 | 79 | 50 |
Shares Outstanding (Diluted) | 77 | 77 | 82 | 85 | 79 | 50 |
Shares Change (YoY) | -3.55% | -5.56% | -3.60% | 7.75% | 56.10% | 3.93% |
EPS (Basic) | -234.70 | -234.50 | -270.00 | -109.81 | -316.34 | -533.20 |
EPS (Diluted) | -234.70 | -234.50 | -270.00 | -110.00 | -316.34 | -533.20 |
Free Cash Flow | -11,159 | -11,775 | -897.74 | -12,506 | -22,277 | -24,407 |
Free Cash Flow Per Share | -144.53 | -152.29 | -10.96 | -147.25 | -282.63 | -483.37 |
Gross Margin | 3.45% | 4.99% | 5.57% | 5.72% | 9.07% | 1.25% |
Operating Margin | -29.76% | -26.97% | -21.16% | -19.38% | -55.04% | -90.33% |
Profit Margin | -29.29% | -26.76% | -28.57% | -12.26% | -93.60% | -117.18% |
Free Cash Flow Margin | -18.04% | -17.38% | -1.16% | -16.45% | -83.63% | -106.23% |
EBITDA | -15,576 | -15,134 | -12,918 | -11,221 | -12,273 | -18,643 |
EBITDA Margin | -25.18% | -22.34% | -16.69% | -14.76% | -46.07% | -81.14% |
D&A For EBITDA | 2,833 | 3,136 | 3,458 | 3,512 | 2,389 | 2,111 |
EBIT | -18,409 | -18,270 | -16,376 | -14,733 | -14,662 | -20,754 |
EBIT Margin | -29.76% | -26.97% | -21.16% | -19.38% | -55.04% | -90.33% |
Advertising Expenses | - | 323.9 | 520.5 | 299.56 | 456.54 | 443.63 |